Introduction
VVC, vaginitis
VULVOVAGINAL SIGNS AND SYMPTOMS, VULVOVAGINAL CANDIDIASIS, VAGINITIS
Vulvovaginal candidiasis (VVC), the second most common cause of vaginitis, negatively impacts the quality of life of affected women.Approval of ibrexafungerp for the treatment of acute VVC was based, in part, on results from two identical phase three studies (VANISH 303 and VANISH 306).The definition of efficacy end points in the VANISH studies differed from those previously reported in VVC studies, with one of the most significant differences being the definition of clinical cure. In previous studies, clinical cure has been reported as a resolution of all signs and symptoms, with a total severity score ≤2 (vulvovaginal signs and symptoms [VSS] ≤2), whereas clinical cure in the VANISH studies was defined as the absence of all VSS of VVC (VSS score = 0).While the efficacy of ibrexafungerp in acute VVC has already been established in previous studies,